Advances on Immunotherapy for Osteosarcoma

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2024 Sep 8

PMID 39245737

Authors

Shengnan Yu

Xudong Yao

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma is the most common primary bone cancer in children and young adults. Limited progress has been made in improving the survival outcomes in patients with osteosarcoma over the past four decades. Especially in metastatic or recurrent osteosarcoma, the survival rate is extremely unsatisfactory. The treatment of osteosarcoma urgently needs breakthroughs. In recent years, immunotherapy has achieved good therapeutic effects in various solid tumors. Due to the low immunogenicity and immunosuppressive microenvironment of osteosarcoma, immunotherapy has not yet been approved in osteosarcoma patients. However, immune-based therapies, including immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecfic antibodies are in active clinical development. In addition, other immunotherapy strategies including modified-NK cells/macrophages, DC vaccines, and cytokines are still in the early stages of research, but they will be hot topics for future study. In this review, we showed the functions of cell components including tumor-promoting and tumor-suppressing cells in the tumor microenvironment of osteosarcoma, and summarized the preclinical and clinical research results of various immunotherapy strategies in osteosarcoma, hoping to provide new ideas for future research in this field.

Citing Articles

Deep learning models in classifying primary bone tumors and bone infections based on radiographs.

Wang H, He Y, Wan L, Li C, Li Z, Li Z NPJ Precis Oncol. 2025; 9(1):72.

PMID: 40074845 PMC: 11904180. DOI: 10.1038/s41698-025-00855-3.

Identification and functional characterization of T-cell exhaustion-associated lncRNA AL031775.1 in osteosarcoma: a novel therapeutic target.

Wang Y, Yuan J, Guo K, Zhang Z, Zhu J, Arya S Front Immunol. 2025; 16:1517971.

PMID: 40066455 PMC: 11891247. DOI: 10.3389/fimmu.2025.1517971.

A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023.

Shen Y, Shao X, Chen J, Tang X Discov Oncol. 2025; 16(1):255.

PMID: 40019638 PMC: 11871176. DOI: 10.1007/s12672-025-02007-2.

Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics.

Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J Front Immunol. 2025; 16:1539396.

PMID: 39991153 PMC: 11842356. DOI: 10.3389/fimmu.2025.1539396.

Liu G, Fang Y, Li J, Chen Z Discov Oncol. 2025; 16(1):226.

PMID: 39987366 PMC: 11846828. DOI: 10.1007/s12672-025-01970-0.

References

Lagerweij T, Perez-Lanzon M, Baglio S . A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells. J Vis Exp. 2018; (135). PMC: 6101124. DOI: 10.3791/56932. View

Tsai R, Discher D . Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008; 180(5):989-1003. PMC: 2265407. DOI: 10.1083/jcb.200708043. View

Zhang C, Zheng J, Lin Z, Lv H, Ye Z, Chen Y . Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging (Albany NY). 2020; 12(4):3486-3501. PMC: 7066877. DOI: 10.18632/aging.102824. View

Picci P, Sangiorgi L, Rougraff B, Neff J, Casadei R, Campanacci M . Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994; 12(12):2699-705. DOI: 10.1200/JCO.1994.12.12.2699. View

Sundara Y, Kostine M, Cleven A, Bovee J, Schilham M, Cleton-Jansen A . Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2016; 66(1):119-128. PMC: 5222929. DOI: 10.1007/s00262-016-1925-3. View

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

Aran D, Looney A, Liu L, Wu E, Fong V, Hsu A . Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019; 20(2):163-172. PMC: 6340744. DOI: 10.1038/s41590-018-0276-y. View

Kawano M, Itonaga I, Iwasaki T, Tsuchiya H, Tsumura H . Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma. Clin Orthop Relat Res. 2012; 470(8):2288-94. PMC: 3392369. DOI: 10.1007/s11999-012-2299-2. View

Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y . CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023; 621(7980):830-839. DOI: 10.1038/s41586-023-06511-9. View

10.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

11.

Xie L, Xu J, Sun X, Guo W, Gu J, Liu K . Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 2020; 8(1). PMC: 7223462. DOI: 10.1136/jitc-2020-000798. View

12.

Boye K, Longhi A, Guren T, Lorenz S, Naess S, Pierini M . Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021; 70(9):2617-2624. PMC: 8360887. DOI: 10.1007/s00262-021-02876-w. View

13.

Miwa S, Nishida H, Tanzawa Y, Takeuchi A, Hayashi K, Yamamoto N . Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer. 2017; 123(9):1576-1584. DOI: 10.1002/cncr.30606. View

14.

Mason N, Gnanandarajah J, Engiles J, Gray F, Laughlin D, Gaurnier-Hausser A . Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clin Cancer Res. 2016; 22(17):4380-90. DOI: 10.1158/1078-0432.CCR-16-0088. View

15.

Hudecek M, Schmitt T, Baskar S, Lupo-Stanghellini M, Nishida T, Yamamoto T . The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. PMC: 2996114. DOI: 10.1182/blood-2010-05-283309. View

16.

Lazarova M, Steinle A . Impairment of NKG2D-Mediated Tumor Immunity by TGF-β. Front Immunol. 2019; 10:2689. PMC: 6873348. DOI: 10.3389/fimmu.2019.02689. View

17.

Liang H, Cui M, Tu J, Chen X . Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies. Front Cell Dev Biol. 2024; 12:1394339. PMC: 11194413. DOI: 10.3389/fcell.2024.1394339. View

18.

Federman N, Chan J, Nagy J, Landaw E, McCabe K, Wu A . Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906. PMC: 3447386. DOI: 10.1155/2012/126906. View

19.

Chang X, Ma Z, Zhu G, Lu Y, Yang J . New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma. J Bone Oncol. 2021; 29:100372. PMC: 8254115. DOI: 10.1016/j.jbo.2021.100372. View

20.

Sheng G, Gao Y, Yang Y, Wu H . Osteosarcoma and Metastasis. Front Oncol. 2021; 11:780264. PMC: 8702962. DOI: 10.3389/fonc.2021.780264. View